Deals and Data
San Diego's Ligand Pharmaceuticals agreed to buy Neurogen, a Connecticut company that develops drugs for psychiatric and neurological disorders in an $11 million deal.
Biopharmaceutical firm MediciNova agreed to pay about $37 million to buy rival Avigen. The sale is expected to conclude during the fourth quarter. San Diego-based MediciNova is working on a multiple sclerosis treatment while Avigen's drug candidate for spasticity linked to multiple sclerosis failed in a Phase II trial.
Ista Pharmaceuticals Inc., an Irvine-based drug maker, said Wednesday that one of its eye drug candidates met goals in a late-stage clinical trial. Ista said that Xibrom QD did significantly better than a placebo at eliminating eye inflammation 15 days after cataract surgery and achieved a secondary goal of eliminating eye pain a day after surgery.
Flush with funding, Zogenix advances its FDA-approved product.
San Diego-based NexBio demonstrated that its product candidate DAS181, or Fludase, inhibits influenza viral infection in human lung tissue.
Three months after a contentious proxy battle resulted in the ouster of its chairman, the board of directors at San Diego's Amylin Pharmaceuticals has picked a new chairman: Paulo Costa, who formerly headed the U.S. operations of biotech giant Novartis.
UC San Diego Health Sciences has entered into an agreement with Indian Institute of Technology Kharagpur to help establish a medical center in the region. The collaboration, which UCSD is touting as the first of its kind between a U.S. public university and India’s network of IIT schools, gives UCSD medical students and faculty a look into India’s health care system and access to clinical trials. At the same time, the partnership could also push innovative medical technologies in the areas of bioengineering and telemedicine.
Datrix, an Escondido-based maker of portable heart monitors, has been purchased by Minnesota-based IntriCon for $2.5 million, IntriCon said Aug. 13.
Bio-Matrix Scientific Group Inc. has signed an agreement with Therinject LLC to work on the development of a therapeutic cancer vaccine as well as the establishment of a tumor banking facility, according to regulatory filings.
Inovio, fueled by swine flu fear, comes back from the brink with ‘universal’ vaccines.
AltheaDX, a San Diego Company previously known as Althea Diagnostics, raised $3.57 million in a recent venture round that aims to raise a total of $6 million, according to a recent regulatory filing.
San Diego-based Anadys is gearing up for its next big step with its hepatitis C drug.
Intellikine, a San Diego-based company stocked with cash, pushes its portfolio of drugs against biology’s hot targets.
Multigen Diagnostics announced it has received a California CLIA license for its comprehensive diagnostic platform, which the company hopes will help physicians run less investigatory tests and lead to health care savings.
San Diego biotech companies Palkion, Sequel Pharmaceuticals and Auspex Pharmaceuticals each raised as much as $3 million in venture capital for the development of their pipeline treatments.